Ossianix is a drug discovery & development company that utilises natural single domain antibodies called VNARs. These compact antigen – binding domain have long , finger like projections that preferentially seek out buried binding pockets  and active sites that are typically inaccessible to conventional monoclonal antibodies.  VNARs can be readily formatted to produce  mono, bi & tri  -specific antibodies and Ossianix is developing a product pipeline to targets in inflammation, Oncology, Neuroscience, Metabolic & Muscular disease.